Agomelatine, a melatonin agonist with antidepressant properties
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Agomelatine (beta-methyl-6-chloromelatonin), which is structurally homologous to melatonin, is a potent agonist of melatonin MT1 and MT2 receptors as well as an antagonist of serotonin 5-HT(2C) receptors. Agomelatine appears to improve sleep without causing daytime sedation. It has not been found to be associated with sexual side effects and discontinuation symptoms. Three placebo-controlled trials, one of them a dose finding study and two of them pivotal trials, suggest that agomelatine is an antidepressant at doses of 25 - 50 mg/day. Agomelatine appears to be well tolerated, without sexual or cardiac adverse effects, weight gain or discontinuation syndromes. Animal studies suggest a possible neuroprotective action of agomelatine, although there are more data in favor of an anxiolytic effect. Substantially more research is needed to establish its role in the treatment of mood and circadian rhythm disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 2×
“Animal studies suggest that agomelatine can enhance cognition and induce neuroprotective proteins such as brain derived neurotrophic factor (BDNF), which could reverse defective neuroplasticity that has been observed in mood disorders [22]; the latter are associated with downregulation of BDNF, which is corrected by a…”
BackgroundMethodPrevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 1×
“However, adverse effects of SSRIs have emerged that range from sexual dysfunction, gastrointestinal syndromes, extrapyramidal syndromes, bleeding disorders and drug interactions which have sobered this expectation [7-11].”
BackgroundAgomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis
Banasr, M., Soumier, A., Hery, M., Mocaër, E., & Daszuta, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.025 · Cited by 318 · cited 1×
“Both of these actions, as well as actions on the ERK-Akt-GSK3b signaling pathways, may explain increased cell proliferation and neurogenesis in the ventral dentate gyrus of the hippocampus under basal and stressful conditions with chronic (3 week) but not subacute (1 week) or acute (4 h) treatment with agomelatine in…”
BackgroundLeproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167 · cited 1×
“In older normal men, 50 mg/day of agomelatine administered in the evening phase advanced rhythms of cortisol, thyroid and body temperature but did not affect sleep [40].”
Background
Cited by
Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes
The Meta-Analysis of Glucose and Insulin-Related Traits Consortium (MAGIC), Bonnefond, A., Clément, N., Fawcett, K., Yengo, L., Vaillant, E., Guillaume, J.-L., Dechaume, A., Payne, F., Roussel, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.1053 · Cited by 363
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Markers of Oxidative Stress and Neuroprogression in Depression Disorder
Vaváková, M., Ďuračková, Z., & Trebatická, J. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/898393 · Cited by 324
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“Agomelatine Agomelatine (β-methyl-6-chloromelatonin) is a melatonin structural homologue that potently agonizes melatonin-1 (MT1) and MT2 receptors in addition to antagonizing 5-HT2C receptors [111].”
BackgroundChronobiological aspects of nutrition, metabolic syndrome and obesity
Garaulet, M., & Madrid, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.05.005 · Cited by 177
Metadata
- Authors
- Dubovsky, S. L., & Warren, C.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2009-09-17
- Volume
- 18
- Issue
- 10
- Pages
- 1533-1540
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1987236532
- Cited by
- 44
- References
- 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Agomelatine, a melatonin agonist with antidepressant properties. https://app.cochat.ai/papers/10.1517/13543780903292634
- The paper
- Dubovsky, S. L., & Warren, C. (2009). Agomelatine, a melatonin agonist with antidepressant properties. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780903292634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.